

PUMA BIOTECHNOLOGY, INC.  
Form 25  
December 30, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 25**

**NOTIFICATION OF REMOVAL FROM LISTING**  
**AND/OR REGISTRATION UNDER SECTION 12(b)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number: 001-35703**

**Puma Biotechnology, Inc.**

**New York Stock Exchange**

**(Exact name of Issuer as specified in its charter, and name of Exchange  
where security is listed and/or registered)**

**10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA 90024**

**(424) 248-6500**

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

**Common Stock, par value \$0.0001 per share**

**(Description of class of securities)**

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Puma Biotechnology, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

December 30, 2016  
**Date**

By: /s/ Alan H. Auerbach  
**Name: Alan H. Auerbach**

President and Chief Executive  
Officer  
**Title**